Enlicitide Decanoate for arteriosclerosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Aug 2023: Trial registered, NCT06008756
  2. 9 Oct 2023: Trial started, NCT06008756

The trials

NCT06008756: Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

State
Under way
Phase
Phase 3
People
14,550 planned
Started
9 Oct 2023
Primary completion
29 Nov 2029
Arms
Blinded Portion: Enlicitide Decanoate, Open-Label Extension: Enlicitide Decanoate
Results
None posted
  1. 24 Aug 2023: Trial registered
  2. 9 Oct 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Enclitide Chloride, Lipfendra.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.